A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell carcinoma of head and neck, or esophagus, or HER2 overexpressing metastatic breast cancer or gastric cancer
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma|HER2 + Breast Cancer|HER2 + Gastric Cancer|Squamous Cell Carcinoma of Head and Neck|Esophageal Squamous Cell Carcinoma
DRUG: LJM716
Dose-limiting toxicities (DLTs), 4 weeks
Adverse events, 4 months|Serious adverse events, 4 months|Pharmacodynamic response to LJM716 in tumor tissue, 3 months|Frequency of partial responses, complete responses and stable disease according to RECIST, every 2 months|Serum concentration of antibodies to LJM716, 18 months|Progression-free survival, 18 months|Duration of response, 18 months|Serum concentration of LJM716,, 4 months
This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell carcinoma of head and neck, or esophagus, or HER2 overexpressing metastatic breast cancer or gastric cancer